Share tips 2026: this week’s top stock picks

If you’ve been keeping a close eye on share tips 2026, then don’t miss this weekly round-up of the top stocks to consider for your portfolio.

The MoneyWeek share tips 2026 guide pulls together some of the best stocks from top share tipsters around.

As well as the UK financial pages, we look at publications across the pond for investors who want to diversify their holdings internationally.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Investors will undoubtedly want to refresh their finances in the new year – we look at where to invest in 2026 and the best sectors. MoneyWeek's investment writers also share their tips for 2026.

This list is updated weekly.

Share tips 2026: top stock picks of the week

Five stocks to buy

1. Fairfax Financial Holdings (TSE: FFH)
Barron's
Fairfax Financial Holdings is the “closest thing to a mini-Berkshire Hathaway”, says Andrew Bary. The Canadian insurer may actually be a “better bet”. It boasts strong insurance operations, an “excellent” investment record, and “phenomenal” long-term performance. Fairfax targets 15% growth in annual book value, against Berkshire’s high single-digit figure, while its $40 billion market value, compared with Berkshire’s $1.1 trillion, means it’s “easier to grow”. Fairfax’s 1.5 price-to-book ratio matches Berkshire’s, but analysts think the “true figure” is 1.25 times, as some investments are carried below market value. Investments include a 43% holding in a container-ship firm run by a Berkshire alumna. $1,786

2. AstraZeneca (LSE: AZN)
This is Money
AstraZeneca’s prospects for 2026 and beyond are “exciting” thanks to a stronger pipeline of new drugs than rival GSK, says Rosie Murray-West. Its emerging portfolio includes drugs for breast and lung cancer, heart failure and asthma, as well as a potential weight-loss pill. The pharmaceutical giant’s shares, which trade at 18 times future earnings, are pricier than GSK’s, but this reflects the expected “good news” over new treatments. The stock also yields nearly 2%. 13,722p

3. Bunzl (LSE: BNZL)
This is Money
Bunzl, the maker of rubber gloves, paper cups and food wrapping, has traditionally grown by acquisition, says Rosie Murray-West. But investors have been concerned that the company may have “bitten off too much”, as margins have been falling; the stock plunged 36% last year. Yet Bunzl is sticking with its full-year profit guidance, and most of its customers, including the NHS, still need its goods. The share-price weakness is a long-term buying opportunity. 2,082p

4. Wise (LSE: WISE)
Investors’ Chronicle
Low-cost international money-transfer company Wise has 13.4 million active customers, says Arthur Sants. Payment volumes rose 26% in the past year, resulting in 7% growth in cross-border revenue to £441 million – 67% of its fees (the rest came from Wise’s debit card). Half-year top-line growth increased 11%, and it made £297 million from interest income, more than its £255 million pre-tax profit. Rising administrative costs, increasing competition, and a relatively high price/earnings (p/e) ratio are headwinds. But with the macroeconomic environment volatile, note that Wise is “one of the few companies that benefits from higher inflation and interest rates”. 869p

5. Balfour Beatty (LSE: BBY)
Investors’ Chronicle
Engineering firm Balfour Beatty is “doubling down” on power generation, decarbonisation and defence work, as well as capitalising on the rise of public-private partnerships to finance infrastructure projects, says Erin Withey. To protect margins, Balfour is expanding its higher-margin support-services business. UK state spending cuts and weather-related delays to projects are risks. However, Balfour has a hefty cash pile, and its investment portfolio could bolster future cash generation. Balfour’s lower-risk public-sector contracts and role in upgrading Britain’s grid justify its premium valuation. 703p

This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.